News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Release: Phase II Data Evaluating Clinical Benefit of REVLIMID(R) Plus Rituximab for Patients with Untreated Indolent B-Cell Lymphomas Presented at International Conference on Malignant Lymphoma



6/17/2011 10:12:15 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID (lenalidomide) plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin’s lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Lymphoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES